References
- Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994; 92:477–588.
- Abraham-Nordling M, Byström K, Törring O, Lantz M, Berg G, Calissendorff J, et al. Incidence of hyperthyroidism in Sweden. Eur J Endocrinol 2011; 165:899–905.
- Wiersinga WM, Bartalena L. Epidemology and prevention of Graves´ ophthalmopathy. Thyroid 2002; 12:855–860.
- Wiersinga WM. Management of Graves´ ophthalmopathy. Nat Clin Pract Endocrinol Metab 2007; 3:396–404.
- Coulter I, Frewin S, Krassas GE, Perros P, Psychological implications of Graves’ orbitopathy. Eur J Endocrinol 2007; 157:127–131.
- Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: Measurement by the medical outcomes study instrument. Thyroid 1997; 6:885–889.
- Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves´ ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998; 82:773–779.
- Terwee CB, Gerding MN, Gerding MN, Dekker FW, Prummel MF, van der Pol JP, et al. Test-retest reliability of the GO-QOL: a disease-specific quality of life questionnaire for patients with Graves´ ophthalmopathy. J Clin Epidemiol 1999; 9:875–884.
- Kashkouli MB, Heidari I, Pakdel F, Jam S, Honarbakhsh Y, Mirarmandehi B. Change in quality of life after medical and surgical treatment of Graves´ ophthalmopathy. Middle East Afr J Ophthalmol 2011; 1:42–47.
- Terwee C., Wakelkamp I, Tan S, Dekker F, Drummel MF, Wieringa W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002; 146:751–757.
- Abraham-Nordling M, Törring O, Hamberger B, Lundell G, Ballstedt L, Calissendorff J, et al. Graves’ disease: A long-term quality-of-life follow up of patients randomized to treatment with antithyroid drugs, radioiodine, or surgery. Thyroid 2005; 11:1279–1286.
- Abraham-Nordling M, Wallin G, Träisk F, Berg G, Calissendorff J, Hallengren B, et al. Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. Eur J Endocrinol 2010; 163:651–657.
- European Group of Graves´ Orbitopathy (EUGOGO). EUGOGO Atlas, Clinical Evaluation. (27 Dec 2012). http://www.eugogo.eu/clinical_evaluation.php
- Terwee CB, Dekker FW, Mourits MP, Gerding MN, Baldeschi L, Kalmann R, et al. Interpretation and validity of changes in scores on the Graves´ ophthalmopathy quality of life questionnaire (GO-QOL) after different treatments. Clin Endocrinol 2001; 54:391–398.
- European Group on Graves´Orbitopathy (EUGOGO), Mourits MP, Bijl H, Altea MA, Baldeschi L, Boboridis K, Curro N, et al. Outcome of orbital decompression for disfiguring proptosis in patients with Graves´orbitopathy using various surgical procedures. Br J Ophthalmol 2009; 93:1518–1523.
- Fichter N, Krentz H, Guthoff RF. Functional and esthetic outcome after bony lateral wall decompression with orbital rim removal and additional fat resection in Graves´orbitopathy with regard to the configuration of the lateral canthal region. Orbit 2013; 32(4):239–246.
- Tehrani M, Krummenauer F, Mann WJ, Pitz S, Dick HB, Kahaly GJ. Disease-specific assessment of quality of life after decompression surgery for Graves´ ophthalmopathy. Eur J Ophthalmol 2004; 3:193–199.
- Fayers T, Barker LE, Verity DH, Rose GE. Oscillopsia after lateral wall orbital decompression. Ophthalmology 2013; 120:1920–1923.
- Rocchi R, Lenzi R, Marino M, Latrofa F, Nardi M, Piaggi P, et al. Rehabilitative orbital decompression for Graves´orbitopathy: Risk factors influencing the new onset of diplopia in primary gaze, outcome and patients´satisfaction. Thyroid 2012; 11:1170–1175.